Stocks
News
ETFs
Economy
Currencies
Press Releases
Articles from AlivaMab Biologics, LLC
AlivaMab Biologics and Ablexis Congratulate Boulevard Bio on its Launch and the Ongoing Phase 1 Clinical Trial of Bispecific Antibody BLVD101
Fully human dual-antagonist bispecific antibody discovered and engineered at AlivaMab Biologics
By
AlivaMab Biologics, LLC
· Via
ACCESS Newswire
· August 13, 2026
Articles from AlivaMab Biologics, LLC | MarketMinute
